You are here:

tenofovir alafenamide (Vemlidy)

Advice

in the absence of a submission from the holder of the marketing authorisation:

tenofovir alafenamide (Vemlidy®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of chronic hepatitis B in adults and adolescents (aged 12 years and older with body weight at least 35 kg).

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: tenofovir alafenamide (Vemlidy)
SMC Drug ID: 1238/17
Manufacturer: Gilead Sciences Ltd
Indication: Treatment of chronic hepatitis B in adults and adolescents (aged 12 years and older with body weight at least 35 kg).
BNF Category:
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 10 April 2017

Back